Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 5/20 | 0.51 |
| ▸ | LIMK2 | P53671 | 5/20 | 0.49 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.48 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555871 | 0.91 | POLB (0.60) | POLBHTR6LIMK2SLC16A3LIMK1 | |
| SCHEMBL3551856 | 0.89 | SLC16A3 (0.53) | POLBSLC16A3MAPTMEN1KMT2A | |
| SCHEMBL3558881 | 0.88 | CA12 (0.57) | POLBSLC16A3MAPTMEN1KMT2A | |
| SCHEMBL3561244 | 0.87 | ALDH1A1 (0.57) | POLBHTR6LIMK2LIMK1MAPT | |
| SCHEMBL3556021 | 0.87 | KDM1A (0.59) | POLBHTR6LIMK2LIMK1MEN1 | |
| SCHEMBL3559499 | 0.87 | MAPT (0.60) | POLBHTR6LIMK2LIMK1MAPT | |
| SCHEMBL3553771 | 0.87 | CA12 (0.61) | POLBHTR6LIMK2LIMK1MAPT | |
| SCHEMBL3555628 | 0.87 | HTR6 (0.65) | POLBHTR6LIMK2SLC16A3PTGES | |
| SCHEMBL3556538 | 0.85 | METAP2 (0.56) | POLBHTR6LIMK2LIMK1 | |
| SCHEMBL3554836 | 0.85 | POLB (0.64) | POLBHTR6LIMK2SLC16A3LIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | SLC2A1 50/4885POLB 3962/4885HTR6 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.